Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 7, 801-808, July 2006; doi:10.1634/theoncologist.11-7-801
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Higgins, H.
Right arrow Articles by Berger, D. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Higgins, H.
Right arrow Articles by Berger, D. L.

Hepatobiliary

RFA for Liver Tumors: Does It Really Work?

Heather Higgins, David L. Berger

Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA

Key Words. Radiofrequency ablation • Liver tumors • Hepatocellular carcinoma • Liver metastases

Correspondence: David Berger, M.D., Department of General Surgery, Wang Ambulatory Care Center 465, Massachusetts General Hospital, 15 Parkman Street, Boston, Massachusetts 02114-3117, USA. Telephone: 617-724-6980; Fax: 617-724-0067; e-mail:dberger{at}partners.org

The use of radiofrequency ablation (RFA) is increasing in the treatment of both primary and metastatic hepatic tumors. However, the role of RFA has yet to be clearly defined in patients who are still considered amenable to surgical intervention. Future prospective studies are needed to define whether RFA can be used as an alternative to surgery in certain patient populations. In the interim, radiofrequency ablation technology will continue to advance and serve as both a palliative and potentially curative intervention for individuals with hepatic tumors.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
E. E. Johnson, B. H. Yamane, I. N. Buhtoiarov, H. D. Lum, A. L. Rakhmilevich, D. M. Mahvi, S. D. Gillies, and P. M. Sondel
Radiofrequency Ablation Combined with KS-IL2 Immunocytokine (EMD 273066) Results in an Enhanced Antitumor Effect against Murine Colon Adenocarcinoma
Clin. Cancer Res., August 1, 2009; 15(15): 4875 - 4884.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. J. Poston, J. Figueras, F. Giuliante, G. Nuzzo, A. F. Sobrero, J.-F. Gigot, B. Nordlinger, R. Adam, T. Gruenberger, M. A. Choti, et al.
Urgent Need for a New Staging System in Advanced Colorectal Cancer
J. Clin. Oncol., October 10, 2008; 26(29): 4828 - 4833.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. J.A. Haasbeek, S. Senan, E. F. Smit, M. A. Paul, B. J. Slotman, and F. J. Lagerwaard
Critical Review of Nonsurgical Treatment Options for Stage I Non-Small Cell Lung Cancer
Oncologist, March 1, 2008; 13(3): 309 - 319.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.
Advertisement